VolitionRX Current Ratio 2012-2021 | VNRX

VolitionRX current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
VolitionRX Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.01B 5.45
2021-03-31 $0.04B $0.01B 5.78
2020-12-31 $0.02B $0.01B 3.26
2020-09-30 $0.02B $0.00B 5.13
2020-06-30 $0.02B $0.01B 4.76
2020-03-31 $0.01B $0.01B 2.83
2019-12-31 $0.02B $0.00B 4.55
2019-09-30 $0.02B $0.00B 6.26
2019-06-30 $0.02B $0.00B 5.50
2019-03-31 $0.02B $0.00B 6.40
2018-12-31 $0.01B $0.00B 5.96
2018-09-30 $0.02B $0.00B 6.38
2018-06-30 $0.01B $0.00B 3.74
2018-03-31 $0.02B $0.00B 5.70
2017-12-31 $0.01B $0.00B 4.61
2017-09-30 $0.01B $0.00B 5.03
2017-06-30 $0.02B $0.00B 7.56
2017-03-31 $0.02B $0.00B 8.38
2016-12-31 $0.02B $0.00B 10.82
2016-09-30 $0.01B $0.00B 6.39
2016-06-30 $0.02B $0.00B 9.62
2016-03-31 $0.02B $0.00B 12.08
2015-12-31 $0.01B $0.00B 5.56
2015-09-30 $0.01B $0.00B 6.72
2015-06-30 $0.01B $0.00B 7.62
2015-03-31 $0.01B $0.00B 11.44
2014-12-31 $0.00B $0.00B 0.86
2014-09-30 $0.00B $0.01B 0.35
2014-06-30 $0.00B $0.00B 0.64
2014-03-31 $0.00B $0.01B 0.56
2013-12-31 $0.00B $0.00B 1.05
2013-09-30 $0.00B $0.00B 1.40
2013-06-30 $0.00B $0.00B 1.58
2013-03-31 $0.00B $0.00B 0.84
2012-12-31 $0.00B $0.00B 0.93
2012-09-30 $0.00B $0.00B 1.49
2012-06-30 $0.00B $0.00B 1.71
2012-03-31 $0.00B $0.00B 1.05
2011-12-31 $0.00B $0.00B 1.30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.184B $0.000B
Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company's development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00